
Repligen Corporation RGEN
$ 103.38
0.0%
Quarterly report 2026-Q1
added 05-06-2026
Country |
|
IPO year |
1986 |
Industry |
Medical instruments |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
56.2 K |
Market Cap[1] |
$ 5.81 M |
EBITDA (LTM) |
$ 112 M |
P/E (LTM) |
161.23 |
P/S (LTM) |
0.01 |
EPS (LTM) |
0.78 |
Other stocks of industry "Medical instruments"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
$ 60.38 | - | $ 12 B | NYSE,SPB | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | Nasdaq Global Select Market,SPB | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | Nasdaq Global Select Market | ||
|
Repro Med Systems
KRMD
|
$ 3.98 | - | $ 184 M | Nasdaq Capital Market | ||
|
ICU Medical
ICUI
|
$ 122.99 | 0.78 % | $ 3.03 B | Nasdaq Global Select Market,SPB | ||
|
iRhythm Technologies
IRTC
|
$ 114.16 | - | $ 3.65 B | Nasdaq Global Select Market,SPB | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | Nasdaq Capital Market | ||
|
Intuitive Surgical
ISRG
|
$ 428.06 | - | $ 153 B | Nasdaq Global Select Market,SPB | ||
|
Alcon
ALC
|
$ 64.0 | -0.03 % | $ 40.4 B | NYSE | ||
|
LeMaitre Vascular
LMAT
|
$ 99.5 | - | $ 2.25 B | Nasdaq Global Market,SPB | ||
|
Masimo Corporation
MASI
|
$ 178.35 | - | $ 9.51 B | Nasdaq Global Select Market,SPB | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | Nasdaq Capital Market | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | NYSE | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | NYSE American | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | NYSE,SPB | ||
|
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | Nasdaq Capital Market | ||
|
Envista Holdings Corporation
NVST
|
$ 23.86 | - | $ 4.01 B | NYSE | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | NYSE | ||
|
electroCore
ECOR
|
$ 6.43 | - | $ 54.5 K | Nasdaq Global Select Market | ||
|
Haemonetics Corporation
HAE
|
$ 57.12 | - | $ 2.87 B | NYSE,SPB | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | NYSE American | ||
|
STAAR Surgical Company
STAA
|
$ 32.01 | - | $ 1.59 B | Nasdaq Global Market,SPB | ||
|
Glaukos Corporation
GKOS
|
$ 142.15 | - | $ 6.88 B | NYSE,SPB | ||
|
STERIS plc
STE
|
$ 215.98 | - | $ 21.3 B | NYSE,SPB | ||
|
Teleflex Incorporated
TFX
|
$ 130.28 | - | $ 5.81 B | NYSE,SPB | ||
|
InfuSystem Holdings
INFU
|
$ 8.61 | - | $ 178 M | NYSE American | ||
|
Microbot Medical
MBOT
|
$ 1.85 | - | $ 84.7 M | Nasdaq Global Select Market | ||
|
Milestone Scientific
MLSS
|
$ 0.34 | -0.87 % | $ 27.9 M | NYSE American | ||
|
Merit Medical Systems
MMSI
|
$ 62.56 | - | $ 3.7 B | Nasdaq Global Select Market,SPB | ||
|
Utah Medical Products
UTMD
|
$ 63.7 | - | $ 206 M | Nasdaq Global Select Market | ||
|
West Pharmaceutical Services
WST
|
$ 300.19 | - | $ 21.7 B | NYSE,SPB | ||
|
Pulse Biosciences
PLSE
|
$ 27.1 | - | $ 1.83 B | Nasdaq Global Select Market | ||
|
DENTSPLY SIRONA
XRAY
|
$ 10.41 | - | $ 2.08 B | Nasdaq Global Select Market,SPB | ||
|
Retractable Technologies
RVP
|
$ 0.69 | 0.01 % | $ 20.7 M | NYSE American | ||
|
Pro-Dex
PDEX
|
$ 58.65 | - | $ 193 M | Nasdaq Global Select Market | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | Nasdaq Capital Market | ||
|
BioLife Solutions
BLFS
|
$ 21.06 | - | $ 1.01 B | Nasdaq Global Select Market | ||
|
Stereotaxis
STXS
|
$ 1.94 | - | $ 176 M | NYSE American | ||
|
Baxter International
BAX
|
$ 17.78 | - | $ 9.12 B | NYSE,SPB | ||
|
ResMed
RMD
|
$ 202.46 | - | $ 29.6 B | NYSE,SPB | ||
|
AtriCure
ATRC
|
$ 28.15 | - | $ 1.34 B | Nasdaq Global Market,SPB | ||
|
Harvard Bioscience
HBIO
|
$ 5.52 | - | $ 245 M | Nasdaq Global Market | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | Nasdaq Global Select Market | ||
|
AngioDynamics
ANGO
|
$ 11.03 | - | $ 451 M | Nasdaq Global Select Market | ||
|
Becton, Dickinson and Company
BDX
|
$ 144.47 | - | $ 41.6 B | NYSE,SPB | ||
|
Nephros
NEPH
|
$ 3.34 | - | $ 35.4 M | Nasdaq Global Select Market | ||
|
OraSure Technologies
OSUR
|
$ 2.95 | - | $ 217 M | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.